- NBTXR3 has shown significant ability to improve effectiveness of radiotherapy in clinical studies.
- Approximately 60% of all cancer patients receive some for of radiotherapy.
- The company has recently shown positive data in trials combining radiotherapy with checkpoint inhibitors, potentially expanding their market.
- The company's subsidiary, Curadigm, presents an attractive preclinical technology that uses its "Nanoprimer" to enhance the effectiveness of many therapeutic classes, especially nucleic acid-based therapeutics.
For further details see:
Nanobiotix Will Disrupt Oncological Radiotherapy